Abingdon Health Interim Earnings Report

Abingdon Health EPS Results

• Actual EPS: -GBX 0.53
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Abingdon Health Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Abingdon Health Announcement Details

• Quarter: Interim
• Date: 3/24/2025
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Abingdon Health (LON:ABDX) is a world leading contract developer and manufacturer (CDMO) of high-quality rapid tests across all industry sectors, including healthcare, infectious disease, animal health, environmental and self-testing. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and regulatory approval. The Company also markets its own range of self-tests under the Abingdon Simply Test brand (www.abingdonsimplytest.com) and has developed and marketed its own labelled tests. The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology and algorithm that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. Founded in 2008, Abingdon Health is headquartered in York, England.